An observational study in Sarcopenia, Gestational Diabetes Mellitus (GDM) and Pregnancy Complications, sponsored by Istituto di Neuroscienze Consiglio Nazionale delle Ricerche. Recruiting at 3 sites in 2 countries. Open to female participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.
Sponsored by Istituto di Neuroscienze Consiglio Nazionale delle Ricerche · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Sarcopenia with a site in Italy — 29 open to participants now, 32 under way, 1 of them phase 3. Sarcopenia · Italy.
Among the 70 studies in Sarcopenia with a site in Italy, this one is the 14th largest by planned enrollment of the 31 observational ones that give a count, is one of 6 that started in 2025, is one of 31 observational ones, reaches primary completion later than 16 of the 31 other live ones, and was the 57th registered.
1,333 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
Browse Sarcopenia studies →29 of the 70 studies in Sarcopenia with a site in Italy are open now. Recruiting first, the newest first:
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio · Sites in Italy
Ages 50+ · Healthy volunteers
Fondazione Don Carlo Gnocchi ETS · Sites in Italy
Ages 30–75
Lionhealth Srl Società Benefit · Sites in Italy
Ages 18–65
Universita di Verona · Sites in Italy
Ages 65–85
Fondazione del Piemonte per l'Oncologia · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.
This study: 35 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 120 across 455 observational studies indexed under Sarcopenia.
Median enrollment 100 across the 39 interventional studies, 160 across the 31 observational. Of the 25 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 70 have an industry lead sponsor. The 10 most frequent:
Istituto di Neuroscienze Consiglio Nazionale delle Ricerche is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Istituto di Neuroscienze Consiglio Nazionale delle Ricerche has 2 studies filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
5 of the studies in Sarcopenia with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07433946Lionhealth Srl Società BenefitPartial Enteral Nutrition to Prevent Weight Loss and Sarcopenia in IBD Patients at Nutritional Risk - SIMBA | 2026-12-15 |
| NCT04730622Istituto Ortopedico RizzoliStudy of Parameters of Osteosarcopenia in Patients With Hip Fracture | 2026-12-31 |
| NCT07692308I.R.C.C.S Ospedale Galeazzi-Sant'AmbrogioMorphological and Functional Biomarkers of Skeletal Muscle Adaptations in Sarcopenia | 2027-06-03 |
| NCT07511413Fondazione del Piemonte per l'OncologiaGALENOS 1 in Head and Neck, Lung, and Rectal Cancer Patients | 2027-08-30 |
| NCT07883161Fondazione Policlinico Universitario Agostino Gemelli IRCCSTargeted Nutritional Intervention (HMB, Arginine, Glutamine) in Patients With Pancreatic Cancer | 2027-09-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 70 studies in Sarcopenia with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sarcopenia is a syndrome characterized by loss of skeletal muscle mass and strength, and physical performance deterioration. Prevalence of sarcopenia in elderly people is remarkably high (prevalence of about 25% in 60+ years people). In type 2 diabetes (T2D), sarcopenia is emerging as comorbidity of major concern. Sarcopenia, however, is not limited to elderly people, as it can develop also in younger individuals with prevalence around 9% or even higher according to some investigators. Of note, sarcopenia has been reported even in the 20-29 years interval. This interval includes women of childbearing age, thus raising the question whether sarcopenia may occur also in women with gestational diabetes (GDM) and whether this may affect pregnancy outcomes. Also, association between sarcopenia and cognitive impairment has been repeatedly reported, to the point that some authors have emphasized the importance of early sarcopenia recognition for prevention of cognitive impairment. Therefore, our main aims are:
During pregnancy, all women will undergo oral glucose tolerance test (OGTT) for assessment of the glucometabolic condition. Several clinical variables of interest in sarcopenia will also be recorded. As regards the OGTT data, special focus will be on the assessment of insulin resistance, both at fasting and during the dynamic conditions determined by the OGTT. Notably, the special interest for insulin resistance is due to the reason that this type of metabolic alteration is known to be a risk factor for sarcopenia. In fact, all women will then undergo testing for diagnosis of sarcopenia (or presarcopenia), and all data and parameters will be analyzed to identify relationships between sarcopenia-related variables and GDM-related ones. It is worth noting that in consideration of the exacerbated insulin resistance condition often observed in GDM, the investigators expect indeed a not negligible prevalence of sarcopenia (or at least presarcopenia) in GDM women, despite the young (non-elderly) age. In addition, since insulin resistance is often present in pregnancy even in the absence of dysglycemia, the investigators do not exclude to identify some cases of sarcopenia/presarcopenia even in pregnant non-GDM women. This study will be the basis for future studies (also of interventional type), especially in women with GDM for prevention of sarcopenia and related possible pregnancy complication and adverse pregnancy outcomes, as well as for possibly contributing to mitigation of risk for T2D development in later life.
Pregnant women, based on the inclusion and exclusion criteria as outlined above.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least one among the following conditions:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: Sarcopenia tests (for muscle mass, muscle function, physical performance) · Diagnostic Test: Oral Glucose Tolerance Test · Other: Montreal Cognitive Assessment
Diagnostic Test: Sarcopenia tests (for muscle mass, muscle function, physical performance) · Diagnostic Test: Oral Glucose Tolerance Test · Other: Montreal Cognitive Assessment
We are not aware of any other study performing sarcopenia tests in GDM (or in pregnancy in general), with the aim of assessing sarcopenia prevalence in GDM/pregnancy, and related possible adverse pregnancy outcomes.
The OGTT, in combination with the sarcopenia tests, will allow to explore the relationships between the glucometabolic condition and the muscle quality in the pregnant women, either with GDM or with normal glucose tolerance.
The MoCA questionnaire, in combination with the sarcopenia tests, will allow to explore the relationships between the cognitive function the presence of the sarcopenia syndrome in the pregnant women, either with GDM or with normal glucose tolerance.
Prevalence of sarcopenia/presarcopenia in pregnant women with and without gestational diabetes
Time frame: Between week 28 and week 32 of pregnancy
Identification of pre-gestational factors (obstetric history, pre-pregnancy body weight, dietary and physical activity habits) and gestational factors (body mass index, blood pressure, OGTT values) with risk of sarcopenia
Pre-gestational data as well as gestational data, as indicated above, will be collected at visit V1 (week 16-18 for women at high GDM risk or week 24-28 for women not at high GDM risk), whereas sarcopenia diagnosis (visit V2) will occur between week 28 and 32 (sarcopenia diagnosis being necessary to indentify, among the indicated pre-gestational and gestational factors, the risk factors for sarcopenia itself).
Time frame: Between week 16 and week 32 of pregnancy
Assessment of the potential impact of sarcopenia/presarcopenia on pregnancy outcomes (large or small for gestational age, LGA or SGA)
Time frame: Between week 28 and week 32 of pregnancy
Exploration of the potential relationship between sarcopenia (presence or no presence of sarcopenia) and cognitive function in pregnancy (MoCA questionnaire score)
The investigators will assess whether the MoCA questionnaire score is different in women with and without sarcopenia.
Time frame: Between week 28 and week 32 of pregnancy
Assessment of the potential impact of sarcopenia/presarcopenia on pregnancy outcomes (type of delivery)
Time frame: At the time of delivery
Not enrolling at this site.
Plan to share: Undecided
Started May 2025 (actual). Primary completion is estimated for Apr 2026, 11 months after the start.
Of 192 non-industry observational studies under Sarcopenia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 63. This study's planned 11 months is below that.
Counting every sponsor, half of 194 studies reached it within 26 months; a quarter within 12 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istituto di Neuroscienze Consiglio Nazionale delle Ricerche